Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank

Shandong Sino Pharmaceutical Technology Co., Ltd.
We are professional supplier of Skin whitening products,Skin Rejuvenation products,Weight Less products,Peptide,Antibiotic,Analgesic,Anti-inflammatory,Vitamin,Health care products.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank



Tirzepatide is the world's first GLP-1 /GIP dual-receptor agonist polypeptide drug, mainly used for blood glucose control in type 2 diabetes and chronic weight management in adults. Its CAS number is 2023788-19-2.
I. Mechanism of Action and Core Indications:
Dual-target synergistic mechanism: Simultaneously activating GLP-1 and GIP receptors. The GLP-1 receptor is responsible for delaying gastric emptying, suppressing appetite, and promoting insulin secretion. GIP receptors promote fat breakdown and enhance energy utilization, dual regulating metabolism. Their effects in blood sugar control and weight loss are superior to those of single-target GLP-1 drugs.
Approved indications
Adult type 2 diabetes (diet + exercise assistance to improve blood sugar).
2. Chronic weight management in adults who are obese (BMI≥28 kg/m²) or overweight (BMI≥24 kg/m²) with weight-related complications (such as hypertension, dyslipidemia, etc.).
Contraindicated groups: Patients with a history or family history of medullary thyroid carcinoma (MTC), and those with type 2 multiple endocrine tumor syndrome (MEN2). Patients with type 1 diabetes and diabetic ketoacidosis are not recommended to use it.
The administration method is subcutaneous injection once a week, and it can be administered in the abdomen, thigh or upper arm
Dose titration starts at 2.5 mg (4-week adaptation period) → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (maximum dose)
The hypoglycemic effect reduces HbA1c by 1.8% to 2.3%, which is superior to that of single-target GLP-1 drugs
A dose of 15 mg can reduce weight by approximately 16-22.5% in a year, which is significantly better than semaglutide
Common adverse reactions include mild to moderate gastrointestinal reactions (nausea, diarrhea, and vomiting), which are relieved over time with medication



